#300
Alpha Score 62.6
seedy19tron
Biotech trader, L/S
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
Long
Mar 20
$121.00
-19.0%
ABVX management signals positive developments including a new CCO hire and optimistic maintenance data.
ABVX management signals positive developments including a new CCO hire and optimistic maintenance data.
Healthcare
Long
Mar 31
$72.11
-21.3%
The user expresses a bullish outlook on Nektar Therapeutics.
Healthcare
Long
Apr 16
$9.37
-12.6%
Buy BioCryst Pharmaceuticals as underlying prescription data remains solid and supports the fundamental picture despite ongoing market rumors.
Buy BioCryst Pharmaceuticals as underlying prescription data remains solid and supports the fundamental picture despite ongoing market rumors.
Healthcare
Long
Apr 07
$35.09
-10.6%
Initiating a long position in COGT, with a deeper fundamental dive expected to follow.
Healthcare
Long
May 05
$37.52
-12.3%
Re-enter long $EWTX as part of a cardiovascular-biotech pair, citing overdue exposure and a current buying opportunity.
Re-enter long $EWTX as part of a cardiovascular-biotech pair, citing overdue exposure and a current buying opportunity.
Healthcare
Long
Mar 15
$33.39
+58.8%
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
Healthcare
Long
May 05
$76.53
-12.4%
Re-enter long $CYTK alongside $EWTX for cardiovascular biotech exposure, with the speaker calling this a solid entry.
Re-enter long $CYTK alongside $EWTX for cardiovascular biotech exposure, with the speaker calling this a solid entry.
Healthcare
Long
Mar 31
$121.94
+5.7%
The user anticipates outperformance for the XBI biotech ETF following double M&A activity.
Healthcare
Long
Mar 25
$52.86
+0.2%
The tweet suggests a positive outlook for TERN following news of an acquisition.
Healthcare
Long
Jun 12
$14.05
-
Buy ERAS as the lower-cost RAS-side M&A alternative for large-cap acquirers (MRK, AZN, BMY) who miss out on RVMD; positioned as the "value option" in the same oncology combination-therapy consolidation wave.
Buy ERAS as the lower-cost RAS-side M&A alternative for large-cap acquirers (MRK, AZN, BMY) who miss out on RVMD; positioned as the "value option" in the same oncology combination-therapy consolidation wave.
Healthcare
Long
Jun 12
$153.87
-6.3%
Buy RVMD as a prime M&A target: TNGX data validates pan-RAS(ON) + PRMT5 two-hit combination, and AMGN, AZN, BMY (PRMT5 holders via MRTX/BMY deal) need to acquire the RAS half; MRK and ABBV already ran diligence on RVMD.
Buy RVMD as a prime M&A target: TNGX data validates pan-RAS(ON) + PRMT5 two-hit combination, and AMGN, AZN, BMY (PRMT5 holders via MRTX/BMY deal) need to acquire the RAS half; MRK and ABBV already ran diligence on RVMD.
Healthcare
Long
Jun 12
$30.94
-7.3%
Buy TNGX as both the data catalyst (pan-RAS(ON) + PRMT5 combination validation) and a potential acquisition target; author sees MRK as a possible acquirer of TNGX paired with ERAS in back-to-back deals.
Buy TNGX as both the data catalyst (pan-RAS(ON) + PRMT5 combination validation) and a potential acquisition target; author sees MRK as a possible acquirer of TNGX paired with ERAS in back-to-back deals.
Healthcare
Long
May 29
$4.68
+81.0%
Author re-enters $REPL long, citing a shift in FDA direction after key personnel exits as catalyst for improved regulatory outlook.
Author re-enters $REPL long, citing a shift in FDA direction after key personnel exits as catalyst for improved regulatory outlook.
Healthcare
Long
Apr 03
$59.33
-6.3%
BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.
BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.
Healthcare
Long
Apr 03
$152.84
-3.1%
BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.
BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.
Healthcare
Showing 15 of 16 picks · sorted by mentions
Choose a mentions count to open ticker posts.
seedy19tron has 16 trade ideas tracked on Buzzberg across 16 tickers since March 2026. Win rate 27% across 15 evaluated calls, average return +1.9%. Ranked #300 on the Buzzberg Alpha leaderboard. Most covered: ABVX, NKTR, BCRX.